AV-412

DRUG2 trials

Sponsors

AVEO Pharmaceuticals, Inc.

Conditions

Advanced CancerRefractory CancerTumor

Phase 1

Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

TerminatedNCT00381654

AVEO Pharmaceuticals, Inc.Tumor

Start: 2006-10-31End: 2010-02-28Updated: 2011-10-04

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

CompletedNCT00551850

AVEO Pharmaceuticals, Inc.Advanced Cancer, Refractory Cancer

Start: 2007-10-31End: 2010-05-31Updated: 2011-10-04